Simulations Plus Sees Software Growth Offset by Margin Pressure
Event summary
- Simulations Plus reported Q2 FY26 revenue of $24.3 million, an 8% increase year-over-year.
- Software revenue grew 9% to $14.6 million, representing 60% of total revenue, while services revenue increased 8% to $9.7 million.
- The company is revising its FY26 adjusted diluted EPS guidance range from $1.03 - $1.10 to $0.75 - $0.85 due to a higher effective tax rate.
- Backlog increased approximately 18% during the quarter, driven by strong bookings.
The big picture
Simulations Plus operates in a niche market providing software and services to accelerate drug development, a sector increasingly reliant on AI and advanced modeling. While the 8% revenue growth demonstrates continued demand for their solutions, the revised guidance and margin compression suggest increased competitive pressure and potential macroeconomic headwinds impacting biopharma R&D spending. The company's ability to maintain its position as a leader will depend on its ability to innovate, manage costs, and adapt to evolving client needs.
What we're watching
- Margin Dynamics
- The significant drop in gross margin from 59% to 66% in Q2, followed by a 63% margin in the six-month period, warrants investigation into cost pressures and pricing strategies, particularly as the company navigates increased tax rates. Further margin contraction could signal competitive headwinds or execution challenges.
- Software Mix
- The decline in clinical operations software revenue, partially offset by growth in discovery and development solutions, suggests a potential shift in biopharma spending priorities. Whether Simulations Plus can maintain software revenue growth by expanding into new areas or upselling existing clients will be crucial.
- Guidance Accuracy
- The substantial downward revision of the full-year EPS guidance highlights the challenges in forecasting profitability, particularly given the variability of certain expense items. The company's ability to achieve the revised guidance will be a key indicator of its operational control and market resilience.
Related topics